Rapport Therapeutics CEO Executes $285K Stock Sale Amid Advancements in Epilepsy Drug Trials
Abraham Ceesay, CEO of clinical-stage biotech firm Rapport Therapeutics, sold just over 10,900 shares valued at approximately $285,000 in two transactions under a pre-established trading plan. These dealings occur as the company expedites Phase 3 trials for its epilepsy drug RAP-219, earning favorable analyst responses and raising price targets for…